The Price of Access: Specialty Drug Affordability, Benefit-Design Erosion, and the Administrative Burden of American Care

American health care has achieved a paradox: unprecedented therapeutic capability paired with declining financial access to it. The decade produced curative antivirals, disease-modifying obesity therapies, targeted migraine biologics, and refined perioperative pathways — and simultaneously produced a benefit environment in which the median commercially insured family now confronts premiums near $25,570, deductibles that routinely exceed $1,700, and list prices for single agents that can exceed a household's entire annual health budget.^1,2 The question before policymakers, health systems, and employers is therefore no longer whether effective care exists, but whether the financing architecture transmits it to the patient at a price compatible with adherence.

This report, prepared by the Havellum Institute for Health Policy & Clinical Economics, examines that transmission failure across three coupled layers. The first layer is the price layer: wholesale acquisition costs, rebates, and net pricing for high-visibility specialty classes — above all the GLP-1 receptor agonists (semaglutide, tirzepatide) whose cultural and clinical prominence has made them the defining affordability controversy of the 2020s.^5,6 The second is the benefit-design layer: premium growth, deductible escalation, copay-accumulator programs, and formulary exclusion that determine what share of the price layer reaches the patient's checking account. The third is the administrative layer: prior authorization, exemption and waiver pipelines under the Americans with Disabilities Act (ADA), the Family and Medical Leave Act (FMLA), National Collegiate Athletic Association (NCAA) medical-waiver regimes, and employer coverage waivers — a largely invisible tax of documentation, delay, and denial that functions as a de facto utilization control.

The analytical core of the report is the Havellum Synthetic Beneficiary Cohort (HSBC-2025), a microsimulation of 12,480 beneficiaries constructed to mirror published epidemiology and benefit benchmarks. We deliberately modeled four high-prevalence, high-recurrence condition families — chronic insomnia, migraine, trauma-spectrum illness, and postoperative recovery — because they are the conditions in which affordability decisions are made most frequently, most repetitively, and with the most direct consequences for labor force participation. Section 2 establishes the clinical and epidemiological context; Section 3 maps the socio-legal frameworks that mediate access; Section 4 presents the empirical results across six interactive visualizations; Section 5 addresses the ethical, privacy, and dispute-resolution tensions these systems create; Section 6 issues ten strategic recommendations; and Section 7 concludes with AMA-formatted references.

The four condition families examined here were selected because they share a consequential architecture: high prevalence, chronic or recurrent courses, dependence on sustained pharmacotherapy, and substantial — but contestable — functional impairment. Each sits at a different point of the affordability spectrum, from near-generic commodity drugs to biologics priced at five figures, which makes them an ideal instrument for isolating where cost actually blocks care.

Illustrative — Specialty Pharmacy Dispensing Environment

2.1Chronic Insomnia: The Under-Priced, Under-Treated Baseline

Chronic insomnia disorder affects roughly 10% to 30% of adults depending on diagnostic stringency, with comorbidity concentrated in exactly the populations this report models: patients with migraine, post-traumatic stress, and postoperative pain states.¹⁴ Its economic signature is unusual. Direct pharmacologic cost is comparatively low — doxepin, trazodone, and compounded melatonin regimens sit at the generic end of the market — yet the newest mechanistic class, the dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant), carries monthly list prices in the $400–$600 range, placing them squarely in deductible-exposure territory for high-deductible health plan (HDHP) enrollees.¹⁴ The dominant economic harm of insomnia is indirect: presenteeism, error rates, and situational exacerbation under shift work and caregiving schedules. In the HSBC-2025 cohort, insomnia beneficiaries filed accommodation requests at nearly twice the rate of matched controls, most commonly seeking schedule flexibility and environmental sleep hygiene modifications — interventions that are inexpensive to grant but administratively costly to document.

2.2Migraine: A Biologic Era Meets a Generic-Era Benefit Design

An estimated 39 million Americans experience migraine; roughly one-third of eligible patients meet criteria for preventive therapy, and the condition accounts for a substantial share of neurological disability-adjusted life-years in working-age adults.^15,16 The therapeutic landscape bifurcates sharply by price. Triptans and older preventives (topiramate, propranolol, amitriptyline) are generic and inexpensive. The CGRP-targeted monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and the oral gepants (rimegepant, atogepant) price at approximately $7,000 to $10,500 per year at list.¹⁶ This bifurcation makes migraine a natural experiment in step therapy: nearly every commercial payer enforces failure of two or three generic preventives before approving a CGRP agent, a sequence that typically consumes four to nine months of ongoing disability. In the cohort, median time from first preventive indication to CGRP initiation was 214 days among commercially insured beneficiaries — a delay that is simultaneously clinical, economic, and administrative in origin.

2.3Trauma-Spectrum Illness: Documentation as a Second Injury

Lifetime prevalence of post-traumatic stress disorder in US adults approximates 6% to 7%, with markedly higher concentrations in populations intersecting the justice, military-transition, and collegiate-athletics systems examined later in this report.¹⁷ Pharmacotherapy (SSRIs, SNRIs, prazosin for trauma-associated nightmares) is inexpensive; the affordability problem in trauma care is the psychotherapy and continuity bundle — prolonged exposure, cognitive processing therapy, and EMDR delivered in 12- to 16-session arcs that network adequacy and visit-limit benefit designs routinely interrupt. Trauma-informed clinical waivers, the institutional instrument through which patients obtain modified scheduling, examination protocols, or temporary duty relief, impose a documentation burden that can itself be re-traumatizing when poorly designed. The cohort modeled trauma-informed waiver requests as a distinct pipeline stage and found them the most delay-prone category: median 41 days from filing to decision, versus 24 days for all other categories, driven by the clinical-review intensity required to substantiate non-permanent functional impairment without excessive disclosure.

2.4Postoperative Recovery: The Episode Where Every Deductible Resets

Surgical episodes concentrate affordability stress into a single quarter. Enhanced Recovery After Surgery (ERAS) protocols have demonstrably reduced length of stay and opioid exposure, yet the residual episode — anesthesia, imaging, post-acute physical therapy, and increasingly common non-opioid adjunctive analgesics — routinely generates multi-party billing in which out-of-network ancillary providers bill into in-network episodes.¹⁸ The No Surprises Act mitigated the most acute balance-billing scenarios, but its independent dispute resolution mechanism has been litigated into partial instability, and the cohort still showed median surprise-bill exposure of $760 per surgical episode after adjustments. Postoperative insomnia and migraine exacerbation are common sequelae, tying this condition family back to Sections 2.1 and 2.2: the beneficiary does not experience four separate conditions but one compounding affordability cascade.

Between the clinician's order and the patient's receipt of care stands a lattice of statutes, regulations, and institutional rules. These frameworks were constructed as civil-rights and labor protections, yet in practice they also function as affordability instruments: they determine who may obtain modified duties, protected leave, medically indicated exemptions, and coverage waivers — and at what documentary price.

3.1ADA Titles I–III: Reasonable Accommodations as Economic Infrastructure

Title I of the ADA obligates covered employers to provide reasonable accommodations to qualified individuals with disabilities through a documented interactive process; Titles II and III extend nondiscrimination and effective-communication obligations to public entities and places of public accommodation, including clinics, pharmacies, and campus health services.^9,21 The affordability relevance is direct. A schedule accommodation granted to a beneficiary with chronic insomnia or migraine can preserve employment-based insurance — the coverage vehicle through which 153 million Americans receive benefits — whereas a denied or delayed accommodation can precipitate the exact coverage gap that converts a manageable condition into a catastrophic bill. Reasonable accommodations under ADA Title II/III in clinical settings (extended appointment windows, low-stimulation environments, environmental sleep hygiene protocols in inpatient units) are low-cost but sit inside the same documentation machinery as costlier employment accommodations. In HSBC-2025, accommodation requests citing migraine and insomnia carried the highest initial-denial rates (22% and 19% respectively), most frequently for insufficient functional-limitation narrative — a documentation quality problem, not a clinical one.

3.2FMLA: Protected Leave Without Protected Income

The Family and Medical Leave Act guarantees up to 12 weeks of unpaid, job-protected leave for eligible employees of covered employers — an eligibility matrix that excludes roughly four in ten US workers through firm-size, tenure, and hours thresholds.¹⁰ For the affordability question, FMLA's structural gap is wage replacement. A postoperative recovery requiring six weeks of leave translates, at the cohort's median wage, into $7,400 of foregone income occurring in the same plan year as deductible reset. The report models this foregone income as an implicit out-of-pocket cost because beneficiaries consistently experience it as such: it competes, dollar for dollar, with pharmacy cost-sharing. The interaction is regressive — lower-wage beneficiaries are both less likely to be FMLA-eligible and less able to absorb the leave-induced income shock, concentrating affordability failure precisely where clinical need is least discretionary.

3.3NCAA Medical Waivers and Roster Compliance

Collegiate athletics constitute a micro-jurisdiction with its own affordability regime. NCAA bylaws governing eligibility, medical hardship waivers (the so-called medical redshirt), and institutional obligations for injury and illness coverage create a setting in which a student-athlete's access to care is conditioned on roster status, scholarship terms, and catastrophic-injury insurance thresholds.¹¹ Non-permanent functional impairment — concussion sequelae, post-surgical recovery, trauma-associated sleep disturbance — must be documented to a standard sufficient for waiver approval yet restrained enough to protect the athlete's privacy and future insurability. Our modeling of an athletics-department pipeline (Section 4, Figure 4) treated each roster transaction, insurance verification, and waiver submission as a billable administrative event; the median athletics medical-waiver file touched 5.2 distinct offices before final disposition. Trauma-informed clinical waivers for student-athletes with PTSD-spectrum diagnoses present the sharpest tension: the very disclosure required to obtain relief can impair the athlete's position in roster decisions, creating a chilling effect we quantify in Section 5.

3.4Employer Health Waivers, Opt-Outs, and Wellness Carve-Outs

Employers increasingly deploy coverage waivers and opt-out incentives — cash payments for declining employer coverage, spousal surcharges, and wellness-program premium differentials under the ACA/HIPAA incentive rules — as cost-containment instruments. Modeled naively, these are actuarially sound; modeled behaviorally, they sort risk. Higher-income, lower-morbidity employees take the opt-out cash; higher-morbidity employees retain coverage and absorb the surcharges. The HSBC-2025 simulation found that a representative $1,200 opt-out incentive shifted 6.8% of the healthy-risk segment off-plan while raising the residual pool's average claims cost by 3.1% — a cross-subsidy reversal that eventually reprices premiums for exactly the beneficiaries with the chronic conditions in Section 2. Wellness carve-outs for biometric screening likewise penalize beneficiaries whose GLP-1 or metabolic regimens are mid-titration, converting a clinical transition into a premium event.

3.5The Inflation Reduction Act and Price Transparency: The Regulatory Counterweight

Two federal instruments define the forward policy environment. The Inflation Reduction Act's Medicare Drug Price Negotiation Program selected ten drugs for initial negotiation (effective 2026) and fifteen for the second round, with maximum fair prices ranging from 25% to 79% below list; obesity and diabetes agents remain outside Part D negotiation eligibility for now, but the pipeline pressure on GLP-1 pricing strategy is unmistakable.^3,4 Concurrently, hospital and insurer price-transparency rules require machine-readable files of gross and negotiated charges and consumer-facing displays of shoppable services; compliance audits continue to find material noncompliance and unusable files, which Section 4 quantifies. Together these instruments attack the price layer directly — while Sections 3.1 through 3.4 show that the administrative layer will capture much of the benefit unless managed deliberately.

All figures below derive from the HSBC-2025 microsimulation and are synthetic estimates calibrated to public benchmarks; they are presented as modeled results, not as claims data. Six interactive visualizations decompose the cost-sharing cascade, the coverage-decision trade space, the exemption pipeline, the multidimensional burden profile, the premium trend, and the policy roadmap.

Methods (4.0)

The cohort was generated by Monte-Carlo assignment of condition states (Section 2 prevalences, including 27% multimorbidity overlap), payer mix (61% commercial employer-sponsored, 18% Medicare-eligible, 12% Medicaid dual-eligible pathways, 9% individual market), and benefit designs drawn from 2024 KFF distributions (HDHP enrollment 29%, median single deductible $1,787).^1,22 Drug prices were applied at WAC and netted against published rebate ranges for each class.^5,6,16 Administrative events (prior authorizations, appeals, exemption filings, roster transactions) were costed at fully loaded staff time. All dollar figures are FY2024 dollars. Chart libraries render client-side; figures are interactive on hover.

The waterfall exposes the central design flaw of HDHP-era benefits: the protections exist, but they engage only after the beneficiary has already financed the peak of exposure. The GLP-1 coinsurance segment alone ($2,980) exceeds the median deductible, meaning that for beneficiaries early in their plan year, the first specialty fill is predominantly patient-financed. Copay-accumulator programs further erode the apparent protection: manufacturer assistance that would have offset the CGRP segment is counted toward the accumulator but, in roughly one-third of modeled plans, not toward the true out-of-pocket maximum, deferring catastrophic relief by an average of 2.3 months.

The matrix is offered as a formulary-governance instrument rather than a verdict. The cohort simulation shows that when northeast-quadrant agents are managed with blunt exclusion, total cost of care rises within 18 months as downstream events (surgical episodes, cardiovascular admissions) migrate back onto the plan. Conversely, lower-left agents subjected to step therapy generate pure friction cost with no budget offset. The recommendation implicit in Figure 2 — and made explicit in Section 6 — is tiered administrative intensity proportional to quadrant, not to drug class tradition.

The funnel is the administrative layer made visible. Each stage imposes its own documentation grammar: ADA filings require functional-limitation narratives, FMLA certifications require provider completion of federal forms, NCAA medical waivers require roster-corroborated impairment timelines, and employer waivers require benefits-committee packets. The simulation attributes the stage-two attrition to a median 17-day gap between documentation completion and reviewer assignment; compressing that gap to five days recovers an estimated 1,100 approvals per 12,480 filings — the highest-leverage single fix identified anywhere in this report.

The trend figure establishes the denominator problem: every affordability intervention measured in this report operates against a base that is itself compounding at roughly 5% annually. Benefit redesign that merely shifts cost-sharing therefore loses ground; only interventions that attack the numerator (net price, administrative cost, episode design) can outpace the trend.

Every affordability mechanism described above is also a data mechanism. Exemption files, waiver packets, roster transactions, and utilization-management records create parallel dossiers whose governance determines whether patients trust — and therefore use — the protections on paper.

5.1HIPAA Minimum Necessary and the Employer-Documentation Conflict

The HIPAA Privacy Rule's minimum-necessary standard collides with the documentation appetites of accommodation and waiver processes.¹² Employers and institutions frequently request complete clinical records when a functional-limitation summary would satisfy the legal standard; athletic departments request diagnostic specificity when impairment timelines would suffice. The report documents three recurring conflict patterns: (1) group health plan claims data being informally visible to benefits administrators adjudicating waivers — a clear segregation failure under 45 CFR 164; (2) FMLA certifications routed through line managers rather than designated leave administrators; and (3) student-athlete treatment records flowing into roster-decision meetings without FERPA/HIPAA-conformant redaction. Each pattern is legally hazardous and, more importantly, behaviorally corrosive: the cohort modeled a 12-point reduction in waiver-filing propensity among beneficiaries who had previously experienced a disclosure breach — suppressed demand that never appears in any denial statistic.

5.2Prior Authorization Ethics and Algorithmic Utilization Management

Prior authorization for northeast-quadrant agents (Figure 2) is defensible when criteria are published, decisions are timely, and denials are reviewable. The cohort found all three conditions violated with measurable frequency: criteria unpublished in 24% of modeled plan documents, decision times exceeding statutory or contractual windows in 18% of cases, and denial letters lacking adequate reasoning in 31%. The introduction of algorithmic pre-screening into PA workflows raises a further duty: institutions deploying predictive denial tools should treat them as clinical decision interventions, subject to the same validation and appeal rights as the decisions they automate. Peer-to-peer review remains the most underused de-escalation instrument — invoked in only 14% of modeled CGRP denials despite reversing roughly half when used.

5.3A Structured Conflict-Resolution Ladder

The report proposes a five-rung ladder, mirrored from ERISA claims procedures, state independent-review organization (IRO) statutes, and No Surprises Act dispute resolution:¹³ (1) internal redetermination within 7 days; (2) peer-to-peer clinical review; (3) external IRO review at plan expense; (4) expedited arbitration for time-sensitive therapies, with interim supply coverage during dispute; and (5) transparency of outcomes — institutions should publish aggregate approval, denial, and reversal rates by drug class and condition family. Publication is the rung most often omitted and the one that disciplines all the others. Rostering conflicts in athletics should follow the same ladder with an added privacy rung: no roster transaction may be conditioned on disclosure beyond the impairment timeline required by the waiver standard.

Ten recommendations follow, grouped by actor. Each is sequenced to deliver benefit within the current regulatory regime rather than awaiting the 2026–2028 changes mapped in Figure 6, and each is traceable to a specific finding in Sections 4 and 5.

Illustrative — Academic Medical Center Implementation Context

The evidence assembled here supports a blunt conclusion: Americans can afford their health system less each year not because medicine stopped working, but because the financing architecture has been quietly re-engineered to transfer price risk downward while leaving administrative complexity upward. The GLP-1 controversy is the most visible symptom, not the disease. The disease is the coupling — list price, benefit design, and documentation friction acting as one mechanism against patients who experience insomnia, migraine, trauma, and surgical recovery as a single life.

The counterweight is equally systemic. The Inflation Reduction Act's negotiation program, transparency enforcement, and the Part D redesign attack the price layer directly; the recommendations in Section 6 attack the administrative layer at points of maximal leverage; and the privacy discipline in Section 5 protects the trust without which neither layer functions. Institutions that treat affordability as a quality metric — published, tracked, and owned at the executive level — will outperform those that treat it as a billing artifact. That is the Havellum position, and it is the standard by which we will score the FY2026–FY2028 policy window mapped in Figure 6.

We close with the obligation of any modeled analysis: these are synthetic estimates, calibrated and disclosed, intended to structure decisions rather than replace them. The patients behind the cohort's distributions are real. The prices are real. The paperwork is real. Affordability is a design choice, and it is being made — by default, every day, in every formulary meeting, waiver packet, and deductible schedule in the country. It should be made deliberately.

References (AMA Style)

1. Claxton G, Rae M, Damico A, et al. Health Benefits in 2024. KFF Employer Health Benefits Survey. KFF; 2024.
2. Centers for Medicare & Medicaid Services. National Health Expenditure data, 2023. CMS website. Updated December 2024.
3. Inflation Reduction Act of 2022, Pub L No 117-169, §11001, 136 Stat 1818 (2022) (codified as amended at 42 USC §1320f).
4. Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: initial selected drugs and second-round selection. CMS fact series; 2023–2024.
5. US Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. FDA; revised 2024.
6. US Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. FDA; 2023.
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340.
9. ADA National Network. Americans with Disabilities Act: Title I (employment), Title II (public entities), Title III (public accommodations). ADANetwork.org; 2023.
10. Family and Medical Leave Act of 1993, 29 USC §2601 et seq.
11. National Collegiate Athletic Association. 2024-25 NCAA Division I Manual: Bylaws 14 (eligibility) and 16 (student-athlete benefits). NCAA; 2024.
12. Standards for privacy of individually identifiable health information (HIPAA Privacy Rule), 45 CFR pt 164.
13. No Surprises Act, div BB of the Consolidated Appropriations Act, 2021, Pub L No 116-260, 134 Stat 2863 (2020).
14. Roth T. Insomnia: definition, prevalence, epidemiology, and differential diagnosis. Sleep. 2007;30(suppl):S3-S5.
15. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries, 1990–2019. Lancet. 2020;396(10258):1204-1222.
16. Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10285):1603-1618.
17. Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. J Trauma Stress. 2013;26(5):537-547.
18. Memtsoudis SG, Cozowicz C, Bekeris J, et al. Enhanced recovery after surgery components and perioperative outcomes: a nationwide observational study. Br J Anaesth. 2019;122(5):638-647.
19. Cutler DM, Feldman NE, Horwitz JR. The costs of administrative complexity in the US health system. Health Aff (Millwood). 2024;43(5):613-621.
20. Bai G, Anderson GF. A more detailed understanding of spending and prices for branded prescription drugs. Health Aff (Millwood). 2021;40(9):1389-1397.
21. Americans with Disabilities Act of 1990, as amended, 42 USC §12101 et seq.
22. Claxton G, Rae M, McDermott D, Damico A. Employee cost sharing in employer health plans: deductibles and out-of-pocket limits. KFF issue brief; 2024.